These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24668939)

  • 1. Development of targeted therapies for Parkinson's disease and related synucleinopathies.
    Sybertz E; Krainc D
    J Lipid Res; 2014 Oct; 55(10):1996-2003. PubMed ID: 24668939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase dysfunction in neurodegenerative disease.
    Brooker SM; Krainc D
    Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lysosomal lair for a pathogenic protein pair.
    Dawson TM; Dawson VL
    Sci Transl Med; 2011 Jul; 3(91):91ps28. PubMed ID: 21753118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
    Stojkovska I; Krainc D; Mazzulli JR
    Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Xilouri M; Brekk OR; Stefanis L
    Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
    Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
    Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
    Sardi SP; Cheng SH; Shihabuddin LS
    Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
    Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocerebrosidase is shaking up the synucleinopathies.
    Siebert M; Sidransky E; Westbroek W
    Brain; 2014 May; 137(Pt 5):1304-22. PubMed ID: 24531622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
    Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
    Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease.
    Wei J; Takamatsu Y; Wada R; Fujita M; Ho G; Masliah E; Hashimoto M
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33672048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.
    Davis MY; Trinh K; Thomas RE; Yu S; Germanos AA; Whitley BN; Sardi SP; Montine TJ; Pallanck LJ
    PLoS Genet; 2016 Mar; 12(3):e1005944. PubMed ID: 27019408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.